AIM ImmunoTech (NYSE:AIM – Free Report) had its target price lowered by Maxim Group from $2.00 to $1.00 in a report released on Tuesday morning, Benzinga reports. Maxim Group currently has a buy rating on the stock.
Separately, Ascendiant Capital Markets lowered their price target on shares of AIM ImmunoTech from $5.25 to $5.00 and set a “buy” rating on the stock in a report on Tuesday, September 3rd.
Check Out Our Latest Analysis on AIM
AIM ImmunoTech Stock Up 3.2 %
AIM ImmunoTech (NYSE:AIM – Get Free Report) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($0.03) earnings per share for the quarter. AIM ImmunoTech had a negative return on equity of 269.04% and a negative net margin of 13,952.74%. The company had revenue of $0.05 million for the quarter. On average, analysts forecast that AIM ImmunoTech will post -0.35 earnings per share for the current fiscal year.
Institutional Trading of AIM ImmunoTech
A hedge fund recently bought a new stake in AIM ImmunoTech stock. Armistice Capital LLC purchased a new stake in AIM ImmunoTech Inc. (NYSE:AIM – Free Report) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 4,078,000 shares of the company’s stock, valued at approximately $1,520,000. Armistice Capital LLC owned about 7.92% of AIM ImmunoTech as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 12.02% of the company’s stock.
AIM ImmunoTech Company Profile
AIM ImmunoTech Inc, an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS).
Featured Articles
- Five stocks we like better than AIM ImmunoTech
- Investing in Commodities: What Are They? How to Invest in Them
- Texas Roadhouse Stock Steering for New Highs This Year
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- How to Start Investing in Real Estate
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for AIM ImmunoTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AIM ImmunoTech and related companies with MarketBeat.com's FREE daily email newsletter.